Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
The following is a round-up of updates by global companies, issued on Wednesday and not separately reported by Allian ...
Mylan NV's combination with Pfizer Inc's Upjohn has been cleared by the US Federal Trade Commission, the two said on ...
Mylan NV on Tuesday said its tie-up with Pfizer Inc unit Upjohn was given the go-ahead by the European Commission. ...
Mylan NV said Friday the US Patent & Trademark Appeal Board has ruled in favour of Mylan in inter partes review proce ...
The European Commission on Wednesday authorised a merger of US drug giant Pfizer Inc's off-patent business unit with ...
Sandoz, a subsidiary of Swiss pharmaceutical giant Novartis AG, has agreed to pay USD195 million to avoid trial on ch ...
Mylan NV and Pfizer Inc have named a number of new board members for Viatris, including a chief financial officer. V ...
Beximco Pharmaceuticals Ltd on Monday said it has signed a commercial agreement with Mylan NV giving it the exclusive ...
Mylan N.V. 01 August 2019 Name: Mylan N.V. Date: 01 August 2019 Re: Mylan N.V. / Upjohn Inc. transaction documents Please click on the following link to view the documents:...
Mylan N.V. 01 August 2019 Name: Mylan N.V. Date: 01 August 2019 Re: Mylan N.V. to combine with Upjohn Inc. Please click on the following link to view the documents:...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
